Xilio Therapeutics (XLO) Depreciation & Amortization (CF) (2020 - 2026)

Xilio Therapeutics has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $344000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 30.78% year-over-year to $344000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 18.26% YoY) and the FY2025 annual result came in at $1.5 million, down 6.27% from the prior year.
• Depreciation & Amortization (CF) rose to $344000.0 in Q1 2026 per XLO's latest filing, from $323000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $499000.0 in Q1 2023 and troughed at $323000.0 in Q4 2025.
• A 5-year average of $428000.0 and a median of $445000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) advanced 25.71% in 2022, then slumped 30.78% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $489000.0 in 2022, then decreased by 8.18% to $449000.0 in 2023, then dropped by 16.26% to $376000.0 in 2024, then decreased by 14.1% to $323000.0 in 2025, then increased by 6.5% to $344000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $344000.0, $323000.0, and $340000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.